ATE466591T1 - Interferon-beta zur antiviralen therapie für atemwegserkrankungen - Google Patents

Interferon-beta zur antiviralen therapie für atemwegserkrankungen

Info

Publication number
ATE466591T1
ATE466591T1 AT05708482T AT05708482T ATE466591T1 AT E466591 T1 ATE466591 T1 AT E466591T1 AT 05708482 T AT05708482 T AT 05708482T AT 05708482 T AT05708482 T AT 05708482T AT E466591 T1 ATE466591 T1 AT E466591T1
Authority
AT
Austria
Prior art keywords
interferon beta
agent
respiratory diseases
antiviral therapy
treatment
Prior art date
Application number
AT05708482T
Other languages
German (de)
English (en)
Inventor
Donna Davies
Peter Wark
Stephen Holgate
Sebastian Johnston
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southampton filed Critical Univ Southampton
Application granted granted Critical
Publication of ATE466591T1 publication Critical patent/ATE466591T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT05708482T 2004-03-12 2005-03-07 Interferon-beta zur antiviralen therapie für atemwegserkrankungen ATE466591T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (1)

Publication Number Publication Date
ATE466591T1 true ATE466591T1 (de) 2010-05-15

Family

ID=32117582

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05708482T ATE466591T1 (de) 2004-03-12 2005-03-07 Interferon-beta zur antiviralen therapie für atemwegserkrankungen

Country Status (12)

Country Link
US (3) US7569216B2 (enExample)
EP (2) EP2206512A3 (enExample)
JP (2) JP4807526B2 (enExample)
AT (1) ATE466591T1 (enExample)
CA (2) CA2787978A1 (enExample)
DE (1) DE602005021078D1 (enExample)
DK (1) DK1734987T3 (enExample)
ES (1) ES2343732T3 (enExample)
GB (1) GB0405634D0 (enExample)
PL (1) PL1734987T3 (enExample)
PT (1) PT1734987E (enExample)
WO (1) WO2005087253A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
JP5172679B2 (ja) * 2005-09-09 2013-03-27 インペリアル イノベーションズ リミテッド 呼吸器疾患の治療のためのインターフェロン−λ療法
CA2622987C (en) * 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
CA2782512A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
CN109293782A (zh) 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
CN111148509A (zh) * 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
EP3923975A4 (en) * 2019-02-13 2023-04-19 University of Florida Research Foundation, Inc. TARGETING A LUNG-RESIDENT TNFR2 + CDC2 (R2D2) SUBPULATION FOR THE TREATMENT OF ASTHMA
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
EP4181944A1 (en) 2020-07-20 2023-05-24 Synairgen Research Limited Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
EP4240396B1 (en) * 2020-11-04 2025-01-01 Ethris GmbH Ifn-lambda mrna for treating viral infections
WO2022154542A1 (ko) * 2021-01-13 2022-07-21 에이비온 주식회사 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
WO2002036628A2 (en) 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
CA2503305A1 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
JP4808157B2 (ja) 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９の均一な調製物
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
AU2005231476B2 (en) 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection

Also Published As

Publication number Publication date
US20070134763A1 (en) 2007-06-14
PT1734987E (pt) 2010-07-06
CA2787978A1 (en) 2005-09-22
EP2206512A2 (en) 2010-07-14
WO2005087253A3 (en) 2005-11-24
US20090257980A1 (en) 2009-10-15
GB0405634D0 (en) 2004-04-21
JP2011144201A (ja) 2011-07-28
EP1734987A2 (en) 2006-12-27
US9089535B2 (en) 2015-07-28
JP2007528890A (ja) 2007-10-18
CA2558212C (en) 2012-11-27
PL1734987T3 (pl) 2010-10-29
EP1734987B1 (en) 2010-05-05
US20130209399A1 (en) 2013-08-15
DK1734987T3 (da) 2010-08-30
DE602005021078D1 (de) 2010-06-17
EP2206512A3 (en) 2013-01-09
ES2343732T3 (es) 2010-08-09
CA2558212A1 (en) 2005-09-22
JP4807526B2 (ja) 2011-11-02
US7569216B2 (en) 2009-08-04
WO2005087253A2 (en) 2005-09-22
US8273342B2 (en) 2012-09-25
HK1097181A1 (en) 2007-06-22

Similar Documents

Publication Publication Date Title
DE602005021078D1 (de) Interferon-beta zur antiviralen therapie für atemwegserkrankungen
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
SG158120A1 (en) Respiratory devices and methods of use
ATE495744T1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
JP2011144201A5 (enExample)
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
EP4210826A4 (en) USE OF ANTIMALARIA AND/OR MUCOLYTIC PROPERTIES IN THE TREATMENT OF VIRAL LUNG DISEASES
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
SG137859A1 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
Steventon et al. Facemask or mouthpiece for delivery of nebulized bronchodilator aerosols?
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
ATE410147T1 (de) Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
MXPA04007294A (es) Composicion para inhalacion.
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
BRPI0606261A2 (pt) formulação de nebulizador
Schaefer et al. SPLUNC1 Enhances TLR3 Signaling in Mouse Lungs
Sperry et al. C52 CRITICAL CARE CASE REPORTS: RESPIRATORY FAILURE/MECHANICAL VENTILATION: Recurrent Pneumonia Caused By Diffuse Laryngotracheal Stenosis As A Consequence Of Prior Prolonged Intubation In A Patient With Systemic Lupus Erythematosus
IL165574A0 (en) Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
Mccoy Oxygen Plus.
GB2430622A (en) Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1734987

Country of ref document: EP